Compare CART & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CART | RDY |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.9B |
| IPO Year | 2023 | 2001 |
| Metric | CART | RDY |
|---|---|---|
| Price | $56.39 | $14.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 5 |
| Target Price | ★ $58.56 | $14.26 |
| AVG Volume (30 Days) | ★ 6.1M | 2.9M |
| Earning Date | 10-29-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | ★ 1.27 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $3,742,000,000.00 | N/A |
| Revenue This Year | $14.60 | $4.59 |
| Revenue Next Year | $10.23 | $12.06 |
| P/E Ratio | $56.19 | ★ $18.67 |
| Revenue Growth | ★ 10.78 | N/A |
| 52 Week Low | $32.73 | $11.36 |
| 52 Week High | $61.73 | $15.67 |
| Indicator | CART | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 77.10 |
| Support Level | $38.62 | $13.99 |
| Resistance Level | N/A | $14.20 |
| Average True Range (ATR) | 2.61 | 0.23 |
| MACD | 0.76 | 0.11 |
| Stochastic Oscillator | 60.75 | 89.58 |
Maplebear (Instacart) is a grocery-focused delivery marketplace that connects national and regional grocers with consumers and couriers, and consumers with their favorite stores. Its app provides on-demand convenience for consumers, lets couriers earn income, and helps grocers scale through digital channels. The marketplace gathers valuable consumer behavior data, attracting consumer-packaged-goods advertisers that seek to reach consumers at the point of purchase. With approximately 600,000 shoppers and 2,200 retail partners, Instacart delivers to about 98% of households in the United States and Canada.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.